Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNF monoclonal antibodies
- Development stage
- Unknown
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
TNF monoclonal antibodies (also known as anti-TNF monoclonal antibodies) are a class of biologic therapies designed to target and neutralize tumor necrosis factor-alpha (TNF-alpha), a key pro-inflammatory cytokine involved in the pathogenesis of various immune-mediated inflammatory diseases. By binding to soluble and transmembrane forms of TNF-alpha, these monoclonal antibodies prevent its interaction with TNF receptors (TNFR1 and TNFR2), thereby downregulating downstream inflammatory cascades. Examples of approved TNF monoclonal antibodies include infliximab, adalimumab, golimumab, and certolizumab pegol. They are widely used in the treatment of chronic inflammatory conditions such as rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis.
- Other names
- TNF monoclonal antibodiesanti-TNF monoclonal antibodiesanti-TNF-alpha monoclonal antibodiestumor necrosis factor monoclonal antibodies
02
Targets
C1Q (Complement C1q)FCGR1A (High affinity immunoglobulin gamma fc receptor I)FcγRII (Fc gamma receptor II)FCGR3B (Low affinity immunoglobulin gamma Fc region receptor III-B)TNFA (Tumor necrosis factor alpha (soluble))TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)TNFR2 (Tumor necrosis factor receptor superfamily member 1B)
Beyond the preview
Go deeper on TNF monoclonal antibodies.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNF monoclonal antibodies.